Denosumab in men with non-metastatic castration-resistant prostate cancer (CRPC) and PSA doubling time (PSADT) ≤6 months - a post-hoc analysis of a randomised trial

被引：0
|
作者：
Wong, S. [1 ]
Miller, K. [2 ]
Smith, M. R. [3 ]
Dearnaley, D. [4 ]
Dogliott, L. [5 ]
Egerdie, B. [6 ]
Fizazi, K. [7 ]
Kueppers, F. [8 ]
Montes De Oca, L. [9 ]
Morote, J. [10 ]
Pavlik, I. [11 ,12 ]
Sieber, P. [13 ]
Tammel, T. J. [14 ]
Van Poppel, H. [15 ]
Wirth, M. [16 ]
Ye, Z. [17 ]
Braun, A. [17 ]
机构：
[1] Western Hosp, Footscray, Vic, Australia
[2] Charite, Berlin, Germany
[3] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[4] Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England
[5] Osped San Luigi Gonzaga, Orbassano, TO, Italy
[6] Urol Associates, Urol Med Res, Kitchener, ON, Canada
[7] Univ Paris Sud, Inst Gustave Roussy, Villejuif, France
[8] Canterbury Urol Res Trust, Christchurch, New Zealand
[9] Ctr Diagnost Urol, Buenos Aires, DF, Argentina
[10] Hosp Valle De Hebron, Barcelona, Spain
[11] Gen Teaching Hosp, Urol Clin, Prague, Czech Republic
[12] Fac Med 1, Prague, Czech Republic
[13] Urol Associates Lancaster, Lancaster, PA USA
[14] Tampere Univ Hosp, Tampere, Finland
[15] Univ Ziekenhuis Gasthuisberg, Louvain, Belgium
[16] Univ Klinikum Carl Gustav Carus, Dresden, Germany
[17] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
BJU INTERNATIONAL | 2013年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
51
引用
收藏
页码：37 / 38
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
    Pang, J. S-T.
    Shore, N.
    Smith, M. R.
    Tammela, T. L.
    Ulys, A.
    Vjaters, E.
    Polyakov, S.
    Jievaltas, M.
    Luz, M.
    Alekseev, B.
    Kuss, I.
    Le Berre, M-A.
    Snapir, A.
    Sarapohja, T.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials
    Carretero-Gonzalez, A.
    Lora, D.
    Manneh, R.
    Lorente, D.
    Castellano, D.
    de Velasco, G.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (11): : 2126 - 2129
  • [23] Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?
    Klaassen, Zachary
    Howard, Lauren
    Wallis, Christopher J. D.
    Janes, Jessica L.
    De Hoedt, Amanda
    Aronson, William J.
    Polascik, Thomas J.
    Amling, Christopher J.
    Kane, Christopher J.
    Cooperberg, Matthew R.
    Terris, Martha K.
    Wu, Yuan
    Freedland, Stephen J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (01) : 151 - 155
  • [24] Prevalence of non-metastatic castration-resistant prostate cancer (CRPC) at high risk of bone metastases in 19 countries in 2013
    Liede, A.
    Arellano, J.
    Hechmati, G.
    Bennett, B.
    Wong, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S710 - S710
  • [25] Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials
    A. Carretero-González
    D. Lora
    R. Manneh
    D. Lorente
    D. Castellano
    G. de Velasco
    Clinical and Translational Oncology, 2020, 22 : 2126 - 2129
  • [26] Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy
    Thomas, Betsan M.
    Smith, Christian
    Evans, Jessica
    Button, Michael R.
    Kumar, Satish
    Palaniappan, Nachi
    Staffurth, John
    Tanguay, Jacob S.
    Lester, Jason F.
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [27] Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy
    Betsan M. Thomas
    Christian Smith
    Jessica Evans
    Michael R. Button
    Satish Kumar
    Nachi Palaniappan
    John Staffurth
    Jacob S. Tanguay
    Jason F. Lester
    Medical Oncology, 2013, 30
  • [28] PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer
    Sakamoto, Shinichi
    Sato, Kodai
    Kimura, Takahiro
    Matsui, Yoshiyuki
    Shiraishi, Yusuke
    Hashimoto, Kohei
    Miyake, Hideaki
    Narita, Shintaro
    Miki, Jun
    Matsumoto, Ryuji
    Kato, Takuma
    Saito, Toshihiro
    Tomida, Ryotaro
    Shiota, Masaki
    Joraku, Akira
    Terada, Naoki
    Suekane, Shigetaka
    Kaneko, Tomoyuki
    Tatarano, Shuichi
    Yoshio, Yuko
    Yoshino, Takayuki
    Nishiyama, Naotaka
    Kawakami, Eiryo
    Ichikawa, Tomohiko
    Kitamura, Hiroshi
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [29] Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial
    Meisel, Alexander
    von Felten, Stefanie
    Vogt, Deborah R.
    Liewen, Heike
    de Wit, Ronald
    de Bono, Johann
    Sartor, Oliver
    Stenner-Liewen, Frank
    EUROPEAN JOURNAL OF CANCER, 2016, 56 : 93 - 100
  • [30] Enzalutamide in Japanese patients with chemotherapy-naive, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial
    Kimura, Go
    Yonese, Junji
    Fukagai, Takashi
    Kamba, Tomomi
    Nishimura, Kazuo
    Nozawa, Masahiro
    Mansbach, Hank
    Theeuwes, Ad
    Beer, Tomasz M.
    Tombal, Bertrand
    Ueda, Takeshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (05) : 395 - 403
12345